NasdaqGS - Delayed Quote • USD
MorphoSys AG (MOR)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:34 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.35 | -0.84 | -3.17 | -1.88 |
| Low Estimate | -1.29 | -1.3 | -6.07 | -3.2 |
| High Estimate | 0.59 | -0.38 | -0.27 | -0.56 |
| Year Ago EPS | -0.36 | -0.57 | -1.48 | -3.17 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 2 |
| Avg. Estimate | 59.48M | 50.3M | 257.5M | 285.62M |
| Low Estimate | 54.6M | 30.88M | 161.99M | 161.45M |
| High Estimate | 64.37M | 69.73M | 324.08M | 409.79M |
| Year Ago Sales | 67.97M | 56.18M | 255.62M | 257.5M |
| Sales Growth (year/est) | -12.50% | -10.50% | 0.70% | 10.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -1.8 | -1.86 | 0.09 |
| EPS Actual | -0.36 | -0.57 | -0.95 | 0.39 |
| Difference | 0.16 | 1.23 | 0.91 | 0.3 |
| Surprise % | 30.80% | 68.30% | 48.90% | 333.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.35 | -0.84 | -3.17 | -1.88 |
| 7 Days Ago | -0.35 | -0.83 | -3.15 | -1.86 |
| 30 Days Ago | -0.35 | -0.84 | -3.2 | -1.9 |
| 60 Days Ago | -0.34 | -0.38 | -1.88 | -0.83 |
| 90 Days Ago | -0.4 | -0.42 | -2 | -0.84 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MOR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 2.80% | -- | -- | 6.50% |
| Next Qtr. | -47.40% | -- | -- | 12.00% |
| Current Year | -114.20% | -- | -- | 5.30% |
| Next Year | 40.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Wells Fargo: Overweight to Equal-Weight | 3/14/2024 |
| Reiterates | Wells Fargo: Overweight to Overweight | 2/5/2024 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 1/19/2024 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 1/16/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 12/15/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 12/5/2023 |
Related Tickers
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
VERA Vera Therapeutics, Inc.
39.65
+2.48%
ALPN Alpine Immune Sciences, Inc.
64.56
-0.09%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
SMMT Summit Therapeutics Inc.
3.8600
+8.73%
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
MRUS Merus N.V.
45.04
+0.24%
JANX Janux Therapeutics, Inc.
47.39
+0.62%
CRNX Crinetics Pharmaceuticals, Inc.
42.12
-0.40%
BPMC Blueprint Medicines Corporation
93.00
+2.50%